Goldman Sachs Maintains Neutral on Pfizer (PFE) Amid Rising Margin Pressure

Pfizer Inc. (NYSE:PFE) ranks among the stocks with the lowest forward PE ratios. On January 23, Goldman Sachs reaffirmed its Neutral rating and $26 price target on Pfizer Inc. (NYSE:PFE), citing the pharma giant’s key hurdles. Pfizer is facing the first of three years of rising patent-cliff strain on its profit margins, as its business development capacity has been slashed to $6 billion and dividend growth has stagnated for the very first time in 16 years.

According to Goldman Sachs, a price rebound will most likely be driven by 2026 clinical catalysts, with investors focusing especially on obesity updates given Pfizer’s recent MTSR acquisition, which puts the company back in the weight loss therapy race.

The coming VESPER-3 monthly data, which could be released in the initial half of 2026 instead of the first quarter, as originally said, is expected to be the most crucial mood driver for PFE shares this year.

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the US and internationally. The company offers medicines and vaccines in various therapeutic areas.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.